<DOC>
	<DOCNO>NCT02636426</DOCNO>
	<brief_summary>Sorafenib oral anticancer drug inhibit multiple protein kinase important tumor growth metastasis , include VEGFR , PDGFR , RAF kinases . In daily clinical practice currently use dose 400 mg twice daily continuous schedule . In phase I study patient treat new dose schedule sorafenib : i.e . high-dose , pulsatile schedule . The tolerability safety new schedule examine exposure escalation cohort base target plasma AUC0-12h ( area curve ) . Exposure escalation cohort use instead conventional dose escalation cohort effect drug dependent AUC level large difference plasma sorafenib AUC0-12h previously show patient treat dose level . Using pharmacokinetic monitoring , sorafenib dose adjust target plasma AUC0-12h . The escalation cohort consist 3-6 patient per exposure level start target plasma sorafenib AUC0-12h level 25-50 mg/L/h . After determination maximum tolerate AUC0-12h , 10 additional patient enter expansion cohort . In expansion cohort patient treat weekly pulse sorafenib maximum tolerate AUC0-12h assessment safety preliminary exploration efficacy .</brief_summary>
	<brief_title>Sorafenib Administered Using High-dose , Pulsatile Regimen : Phase I Exposure Escalation Study</brief_title>
	<detailed_description>Rationale : Preclinical research show improved efficacy sorafenib give high-dose , pulsatile schedule compare conventional ( low dose ) continuous schedule result high peak concentration tumor . In phase I study patient treat high-dose , pulsatile sorafenib exposure escalation cohort . Exposure escalation cohort base target plasma AUC0-12h ( area curve ) use instead conventional dose escalation cohort effect drug dependent AUC level large difference plasma sorafenib AUC0-12h previously show patient treat dose level . Primary Objectives : - To determine maximum tolerated plasma AUC0-12h high-dose sorafenib administer weekly , pulsatile schedule . - To assess safety tolerability high-dose , pulsatile sorafenib . Secondary Objectives : - To determine pharmacokinetic behaviour sorafenib major active metabolite pyridine N-oxide administer weekly , pulsatile schedule . - To determine recommended phase II plasma AUC0-12h high-dose sorafenib weekly pulsatile schedule . - Preliminary assessment efficacy high-dose , pulsatile sorafenib administer maximum tolerated plasma AUC0-12h . - To determine skin intratumoral concentration sorafenib correlation plasma whole blood concentration . - To select 1-2 optimal time point AUC0-12h data determine sorafenib exposure use finger puncture . Study design : A single center , open-label , phase I study high-dose , pulsatile sorafenib administer exposure escalation cohort . Study population : Adult patient locally advance metastatic disease standard therapy exist . Treatment : Patients treat exposure escalation cohort high-dose sorafenib administer weekly pulsatile schedule . Using pharmacokinetic monitoring , sorafenib dose adjust target plasma AUC0-12h . The escalation cohort consist 3-6 patient per exposure level start target plasma sorafenib AUC0-12h level 25-50 mg/L/h . After determination maximum tolerate AUC0-12h , 10 additional patient enter expansion cohort . In expansion cohort patient treat weekly pulse sorafenib maximum tolerate AUC0-12h assessment safety preliminary exploration efficacy .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histological cytological documentation incurable locally advanced metastatic solid malignancy standard therapy exists . 2 . Patients eligible expansion cohort must willing undergo tumor skin biopsy , tumor skin biopsy optional patient enrol escalation cohort . Primary tumor metastatic site must accessible biopsy . Bone metastases exclude biopsy site . 3 . Evaluable disease RECIST version 1.1. criterion ( see appendix III ; least 1 target nontarget lesion dose escalation cohort ; least 1 target lesion dose expansion cohort ) . 4 . Patients must document radiographic clinical progressive disease . 5 . Age ≥ 18 year . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 ( appendix IV ) . 7 . Normal 12lead ECG ( clinically insignificant abnormality permit ) , leave ventricular ejection fraction ( LVEF ) &gt; 50 % evaluate multigated acquisition scan ( MUGA ) echocardiogram . 8 . Normal regulate thyroid function supplementation block drug permit . 9 . Urine analysis : clinically significant abnormality . 10 . Albumin high 25 g/L . 11 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 14 day prior screen : Hemoglobin ≥ 5,6 mmol/L Absolute neutrophil count ( ANC ) ≥ 1,5 x 10*9/l Platelet count ≥ 100 x 10*9/l Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) . Patients know Gilbert 's disease serum bilirubin ≤ 3x ULN may enrol . ALT AST ≤ 2.5 x ULN ( case liver metastasis : ≤ 5 time ULN ) . Serum creatinine ≤ 1.5 x ULN creatinine clearance ≥ 50 ml/min ( base MDRD ) . PTINR/PTT &lt; 1.5 x ULN , unless coumarin derivative use . Activated partial thromboplastin time &lt; 1.25 x ULN ( therapeutic anticoagulation therapy allow , treatment interrupt biopsy judge treat physician ) . 1 . Evidence significant uncontrolled concomitant disease , cardiovascular disease ( include stroke , New York Heart Association Class III IV cardiac disease myocardial infarction within 6 month prior screen , unstable arrhythmia , clinically significant valvular heart disease unstable angina ) ; nervous system , pulmonary ( include obstructive pulmonary disease history symptomatic bronchospasm ) , renal , hepatic , endocrine , gastrointestinal disorder ; serious nonhealing wound fracture . 2 . Prior radiotherapy abdominal thoracic area &gt; 3 vertebra spine ( long interval since previous radiotherapy radiotherapy ≤ 3 vertebra , eligibility decide individual basis primary investigator ) . 3 . Poorly control hypertension despite adequate blood pressure medication . Blood pressure must ≤ 160/95 mmHg time screen stable antihypertensive regimen . Blood pressure must stable least 2 separate measurement . 4 . Seizure disorder require anticonvulsant therapy . 5 . Major surgery , diagnostic surgery , within 4 week prior day 1 , without complete recovery . 6 . Known active bacterial , viral , fungal , mycobacterial , infection ( include HIV atypical mycobacterial disease , exclude fungal infection nail bed ) . 7 . Known hypersensitivity sorafenib excipients . 8 . Presence significant central nervous system psychiatric disorder ( ) would interfere patient 's compliance . 9 . Drug alcohol abuse . 10 . Any evidence disease condition might affect compliance protocol interpretation study result render patient high risk treatment complication . 11 . Unwillingness inability comply study followup procedure . 12 . Chemotherapy , radiotherapy , biologic therapy within previous 4 week ; Nitrosoureas mitomycin C within previous 6 week ; Investigational agent within previous 4 week . 13 . Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis . 14 . Untreated active central nervous system ( CNS ) metastases ( progress require anticonvulsant corticosteroid symptomatic control ) . 15 . Patients history treat CNS metastasis eligible , provide follow criterion meet : Presence evaluable measurable disease outside CNS Radiographic demonstration stabilization upon completion CNSdirected therapy evidence interim progression completion CNSdirected therapy screen radiographic study Completion radiotherapy ≥ 8 week prior screen radiographic study Discontinuation corticosteroids anticonvulsant ≥ 4 week prior screen radiographic study 16 . Pregnant breastfeeding subject . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must agree use adequate barrier birth control measure ( e.g. , cervical cap , condom , diaphragm ) course trial . Oral birth control method alone consider adequate study , potential pharmacokinetic interaction study drug oral contraceptive . Concomitant use oral barrier contraceptive advise . Contraception necessary least 6 month receive study protein kinase inhibitor . 17 . Concomitant medication drug proarrhythmic potential ( sotalol , haloperidol , flecainide ) permit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>phase I study</keyword>
	<keyword>sorafenib</keyword>
	<keyword>high-dose schedule</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>drug monitoring</keyword>
</DOC>